TPP1 and cholangiocarcinoma: According to EORTC criteria, PDAC showed decreases in metabolic activity under ITPP monotherapy (MC: −3.36%), while other tumor types increased (CCA: 17.97%, CRLM: 40.1%, HCC: 15.54%).